Identification of the Genes for Kidney Cancer: Opportunity for Disease-Specific Targeted Therapeutics

W. Marston Linehan,1 Peter A. Pinto,1 Ramaprasad Srinivasan,1 Maria Merino,2 Peter Choyke,3 Lynda Choyke,1 Jonathan Coleman,1 Jorge Toro,4 Gladys Glenn,4 Cathy Vocke,1 Bert Zbar,1 Laura S. Schmidt,1,5 Donald Bottaro,1 and Len Neckers1

Abstract

Recent advances in understanding the kidney cancer gene pathways has provided the foundation for the development of targeted therapeutic approaches for patients with this disease. Kidney cancer is not a single disease; it includes a number of different types of renal cancers, each with different histologic features, a different clinical course, a different response to therapy, and different genes causing the defects. Most of what is known about the genetic basis of kidney cancer has been learned from study of the inherited forms of kidney cancer: von Hippel Lindau (VHL gene), hereditary papillary renal carcinoma (c-Met gene), Birt Hogg Dubé (BHD gene), and hereditary leiomyomatosis renal cell cancer (fumarate hydratase gene). These Mendelian single-gene syndromes provide a unique opportunity to evaluate the effectiveness of agents that target the VHL, c-Met, BHD, and fumarate hydratase pathways.

Kidney cancer affects 36,000 Americans annually, and nearly 12,000 die each year from this disease in the United States (1). Although patients with kidney cancer who present to their physician with localized disease often have long-term survival, patients who present with advanced disease have a 2-year survival of only 18% (2). Kidney cancer is not a single disease; it is made up of a number of different types of cancer that occur in the kidney (3), each with a different histologic type, a different clinical course, a different response to therapy, and different genes causing the defect (4, 5). Clear cell is the most common type (75%), papillary occurs in 10%, and chromophobe renal carcinoma occurs in 5%, with the remaining being made up of collecting duct, medullary, and oncocytoma. It is hoped that understanding the genetic basis of cancer of the kidney will lead to the development of effective forms of therapy for this disease (Fig. 1).

Hereditary Kidney Cancer

Kidney cancer occurs in both sporadic (noninherited) and hereditary (inherited) forms. Most of what is known about the genetic basis of kidney cancer has been learned from study of the hereditary forms of kidney cancer (6). There are four well-defined hereditary types of kidney cancer: von Hippel Lindau (VHL), hereditary papillary renal carcinoma (HPRC), Birt Hogg Dubé (BHD), and hereditary leiomyomatosis renal cell carcinoma (HLRCC).

VHL: Clear Cell Renal Carcinoma

VHL (OMIM 19330) is an inherited cancer syndrome in which affected individuals are at risk of the development of tumors in a number of organs, including the kidneys (7). Patients affected by VHL are at risk of the development of cerebellar and spinal hemangioblastomas, retinal angiomas, endolymphatic sac tumors (8), pancreatic neuroendocrine tumors (9), pheochromocytoma (10), and bilateral, multifocal kidney cancers (11). VHL-associated renal tumors are always clear cell renal carcinoma (12). It has been estimated that VHL patients are at risk of the development of up to 600 tumors and 1,100 cysts per kidney (13).

The VHL gene. Genetic linkage analysis was done in VHL kindreds to identify the VHL gene on the short arm of chromosome 3 (14). Germline mutations of the VHL gene are identified in nearly 100% of VHL families (15). Mutations of the VHL gene have also been found in a high percentage of tumors from patients with sporadic, noninherited clear cell renal carcinoma (16, 17). The VHL gene has the characteristics of a tumor suppressor gene, and alteration of both copies of the gene is found in VHL-associated tumors and sporadic clear cell renal carcinoma (Fig. 2).

Targeting the VHL pathway. The product of the VHL gene forms a complex with elongin C and elongin B (18, 19), CUL2...
(20), and RBX1 (21) to target the hypoxia-inducible factors HIF1α and HIF2α for ubiquitin-mediated degradation (22–24). Understanding the VHL pathway has provided the opportunity to develop therapeutics that target downstream HIF pathway genes vascular endothelial growth factor and platelet-derived growth factor with agents, such as sunitinib, that have high affinity for the vascular endothelial growth factor and platelet-derived growth factor receptors (25). Other approaches, such as targeting HIF transcription (26) and targeting HIF stability (27), are also being evaluated in clinical trials.

**HPRC: Type 1 Papillary**

HPRC (OMIM 164860) is a hereditary cancer syndrome, inherited in an autosomal dominant fashion, in which affected individuals are at risk of the development of bilateral, multifocal, type 1 papillary renal carcinoma (28, 29). It has been estimated that HPRC patients are at risk of the development of up to 3,000 tumors per kidney (30).

*The HPRC gene: the MET gene.* Genetic linkage analysis was done in HPRC kindreds, and the MET proto-oncogene was found to be the HPRC-causing gene (31). Activating mutations in the tyrosine kinase domain have been found in affected individuals in HPRC kindreds. HPRC is a highly penetrant hereditary cancer syndrome that tends to be late onset (32). Recently, however, an early-onset HPRC phenotype has been described (33). MET mutations have also been found in a subset of sporadic, type 1 papillary renal carcinomas (ref. 34; Fig. 3).

**Oncogenic signaling via c-Met.** The MET oncogene was isolated from a human osteogenic sarcoma cell line that had been chemically mutagenized in vitro. Transforming activity was due to a DNA rearrangement where sequences from the translocated promotor region (TPR) locus on chromosome 1 were fused to sequences from the MET locus on chromosome 7 (TPR-MET), a rearrangement that was later found in patients with gastric carcinoma (35, 36). Isolation of the full-length MET proto-oncogene coding sequence revealed structural features of a membrane-spanning receptor tyrosine kinase (35). The identification of hepatocyte growth factor (HGF) as the natural ligand for the c-Met receptor protein and the identity of scatter factor (SF) and HGF united a collection of findings, showing that a single receptor transduced multiple biological activities, including motility, proliferation, survival, and morphogenesis (37–40).

The biochemical and biological effect of these MET mutants has been investigated in several model systems, confirming their suspected oncogenic potential (41–47). Trisomy of chromosome 7, which contains both MET and HGF/SF genes, occurs in 95% of sporadic papillary renal carcinoma (48); a detailed study of trisomy 7 in HPRC revealed nonrandom...
duplication of the mutant MET allele in 100% of tumor samples (49).

Somatic MET mutations have since been found in several other human cancers, including gastric and liver cancer (50, 51), small cell and non–small cell lung cancers (52–54), and metastases of head and neck squamous cell carcinoma (55, 56). Unlike renal carcinoma, where mutations are typically confined to exons encoding the tyrosine kinase domain, these mutations encompass other receptor regions, most notably, the juxtamembrane region, where missense and deletion mutations that delay c-Met down-regulation occur with significant frequency (~12%) in lung cancers (54).

Cancer drug development targeting the c-Met pathway. At least three basic strategies have been used to target this pathway: antagonism of ligand/receptor interaction, inhibition of tyrosine kinase catalytic activity, and blockade of receptor/effector interactions. In addition, combinations of conventional and c-Met–targeted therapies may offer promise for specific cancers (57).

A collection of structure/function studies, including the early discovery that a naturally occurring truncated HGF/SF variant (HGF/NK2) was a specific competitive mitogenic antagonist, led to the development of HGF/NK4, a larger, more antagonistic HGF/SF fragment (58), and to an uncleavable form of pro-HGF/SF (59), both of which block tumor growth and metastasis in animal models. Similarly, the early development of c-Met ectodomain/IgG fusion protein with HGF/SF–neutralizing activity preceded the engineering of a soluble c-Met ectodomain fragments with pathway-neutralizing and antitumor activities (60, 61). Neutralizing mouse monoclonal antibodies against human HGF/SF have also been shown effective antitumor agents in animal models (62–64). The recent development of a fully human monoclonal antibody with HGF/SF–neutralizing and antitumor properties and its introduction into phase 1 human clinical trials are important steps forward (35, 65).

Highly selective synthetic inhibitors of c-Met ATP binding, effective in the nanomolar concentrations in cultured cells (66–73). Of these, the novel indolinone compounds SU11274 and PHA665752 displayed a minimum of 50-fold selectivity for c-Met relative to several other tyrosine kinases and potentially blocked HGF-stimulated activities in cultured cells and tumorigenicity in well-characterized c-Met–driven xenograft models (70). Analysis of SU11274 using cells that express HPRC-associated MET mutants revealed interesting differences in sensitivity (69), and gastric cancer cells with MET gene amplification displayed significantly increased sensitivity to PHA665752 (73), strongly reinforcing the concept that knowledge of genetic alterations should help predict the efficacy of c-Met tyrosine kinase inhibitors for specific patient groups. Not surprisingly, the number of pharmaceutical and biotechnology companies that have announced drug development programs targeting the c-Met tyrosine kinase has grown considerably in the last 3 years.

The requirement of the COOH-terminal docking site for wild-type or mutant c-Met–transforming activity in cultured cells (43, 44) and the known roles of intracellular effectors, including Gab1, phosphatidylinositol 3-kinase 3-kine, growth factor receptor binding protein 2, Src homology and collagen, and signal transducer and activator of transcription 3, in cell transformation (38, 40) suggest that targeting one or more of these interactions could effectively disrupt c-Met–driven oncogenesis. Knowledge of the unique structure of the growth factor receptor binding protein 2 SH2 domain provided the basis for the development of small synthetic growth factor receptor binding protein 2 selective binding antagonists (74). Further refinement of these early structures has yielded compounds that block HGF/SF–stimulated cell motility, matrix invasion, and morphogenesis in normal and tumor-derived cultured cells, as well as vascular endothelial cells, at low nanomolar concentrations (75).

Beyond effector targeting, compounds that block HSP90/client interactions, such as geldanamycin (76), also potently block c-Met oncogenic signaling (77), thus potently, in fact, as to suggest that other mechanisms of drug action may be involved (78). Phase 1 and 2 clinical trials of geldanamycin-related compounds are under way for a variety of cancers where the c-Met pathway is active. Combining agents, such as geldanamycin, which attenuate the supply of new receptors to the cell surface with inhibitors of other specific receptor functions, could lower the effective dose of each, reducing the likelihood of drug toxicity and the selection pressure for drug-resistant mutations.

---

7 http://www.amgen.com/science/pipeline/AMG102.html
BHD: Chromophobe Renal Cell Carcinoma

BHD (OMIM 135150) is a hereditary cancer syndrome in which affected individuals are at risk of the development of cutaneous fibrofolliculomas (79), pulmonary cysts, and renal tumors (80, 81). BHD-associated renal tumors may be chromophobe renal cell carcinoma (33%), hybrid oncocytic renal cell carcinoma (50%), clear cell renal cell carcinoma (9%), or oncocytoma (5%). Clinical management of BHD-associated renal tumors is similar to that of VHL and HPRC renal tumors; surgical removal is often recommended when the renal tumors reach the 3-cm threshold (82).

Identification of the BHD gene. Genetic linkage analysis was done in BHD kindreds to localize (83) the BHD gene on the short arm of chromosome 17 (84). Germline mutations of the BHD gene have been found in 51 (84%) of 61 BHD kindreds evaluated at the National Cancer Institute (85). Twenty-two different mutations have been identified, which are mainly frameshift or nonsense mutations (i.e., mutations that would be predicted to truncate the BHD protein folliculin). Mutations were distributed throughout the gene with no correlation between location or type of mutation and phenotypic features of BHD. More than half of BHD kindreds carry an insertion or deletion in a mononucleotide tract of eight cytosines within exon 11, representing a hypermutable “hotspot” for mutation in BHD. Patients who inherited the C deletion mutation developed renal tumors at a significantly lower frequency (6%) than patients who inherited the C insertion mutation (33%; Fig. 4).

The BHD gene: a novel tumor suppressor gene. The BHD gene has the characteristics of a tumor suppressor gene. When Vocke et al. searched for somatic alterations of the BHD gene in tumor tissue from BHD patients carrying germline BHD mutations, somatic mutations or loss of heterozygosity was detected in 54 (70%) of 77 tumors; intragenic mutations were found in 41 of 77 tumors, and loss of heterozygosity of the 17p11.2 chromosomal region containing the BHD gene was found in 13 (17%) of 77 tumors (86). In all cases, the germline BHD mutant allele was retained, and the wild-type BHD allele was lost. Consistent with these results, BHD mRNA expression was hardly detectable in BHD-associated renal tumors by in situ hybridization (87). Studies are currently under way to identify the BHD gene function and to determine how alteration of this gene leads to kidney cancer (Fig. 5).

HLRCC

HLRCC (OMIM 605839) is a hereditary cancer syndrome in which affected individuals are at risk of the development of cutaneous and uterine leiomyomas and kidney cancer (88). HLRCC-associated kidney cancer is markedly different from that found in VHL, HPRC, or BHD. HLRCC-associated kidney cancer is an extremely aggressive form of the disease; it tends to spread early when the tumors are small. HLRCC kidney cancer is characterized by a microcystic histologic pattern with prominent organophagic nucleoli (89). Affected women in HLRCC kindreds are at risk of developing uterine leiomyomas.
Nearly 90% of the affected women in the North American kindreds seen at the National Cancer Institute were found to have uterine leiomyoma, and 50% had had a hysterectomy before the age of 30 years (refs. 90, 91; Fig. 6).

**The HLRCC gene: fumarate hydratase.** The HLRCC gene was found to be the Krebs cycle enzyme fumarate hydratase (FH; ref. 92). Mutations of the FH gene have been found in 52 (93%) of 56 HLRCC kindreds evaluated at the National Cancer Institute. Thirty-one different germline FH mutations have been identified, consisting of 20 missense, 8 frame shifts (3 insertions and 5 deletions), 2 nonsense, and 1 splice site. Mutations were found throughout the gene except exon 5. Twenty (65%) of the 31 mutations resulted in the substitutions of single amino acid residues that were highly conserved (refs. 90, 91; Fig. 7).

**FH Pathway.** Recently, we reported that HLRCC tumor specimens expressed high levels of both HIF-1α and HIF-2α as well as the HIF target gene GLUT1 when compared with adjacent renal epithelium (93). Elevated HIF levels could be traced to reduced HIF proline-hydroxylation, not to loss of VHL. Using enzyme kinetic analysis, we found fumarate to be a very potent competitive inhibitor of HIF prolyl hydroxylase. Furthermore, we showed that a small elevation in intracellular fumarate, whether induced pharmacologically or by molecular knockdown of FH, is sufficient to up-regulate HIF, GLUT1 expression, glucose uptake, and lactic acid production (Fig. 8). These findings identify biallelic loss of FH as a single gene defect capable of inducing the Warburg effect (the tendency of cancer cells to rely on glycolysis as their energy source). Further experimentation will be needed to fully explore the link between dysregulation of the tricarboxylic acid cycle and tumorigenesis and to more thoroughly elucidate the role of HIF in this process (Fig. 8).

**Targeting the FH pathway in HLRCC kidney cancer.** One approach currently being evaluated in HLRCC kidney cancer is to target the FH pathway with agents such as bevacizumab. Another approach being evaluated is to target the HSP90 pathway with agents such as 17-allylamino-17-desmethoxygeldanamycin (17-AAG). 17AAG, a small-molecule inhibitor of Hsp90, the benzoquinone ansamycin, has shown antitumor activity in several human xenograft models and is currently in clinical trials, both as a single agent and in combination with other therapeutics. Recently, Vanharanta et al. (94), in an expression profile study, reported that NAD(P)H dehydrogenase quinone 1 (NQO1) was markedly overexpressed in FH-deficient uterine fibroids compared with wild-type FH-expressing fibroids. We confirmed very high expression of NQO1 protein in FH-deficient HLRCC tumor specimens compared with tumor tissue from other hereditary renal cancers (Fig. 9). High NQO1 expression predicts for enhanced sensitivity to 17-AAG. In one study, ectopic expression of NQO1 in NQO1-null colon carcinoma cells resulted in a 32-fold increase in the cytotoxicity of 17-AAG (95). This dramatic sensitization to 17-AAG is due to the ability of NQO1 to reduce the benzoquinone moiety of the drug, which results in its markedly improved antitumor activity (96). Thus, HLRCC is expected to be particularly sensitive to 17-AAG. Animal xenograft studies in support of this hypothesis are currently under way.

**Conclusion**

In summary, recent understanding of the kidney cancer gene pathways has provided the opportunity to develop pathway-specific therapies for the different histologic types of this disease. The potential opportunity in studying hereditary cancer syndromes was recently highlighted by Fishman and Porter, who attributed the difficulty of drug discovery to the paucity of targets solidly linked to major diseases. They propose as a solution to validate targets identified in rare Mendelian disorders, where the inheritance of a single-gene mutation is linked to the disease (97). They note that the relationship...
between disease and the signaling pathway is clearest in genetic disorders, and that there is a clear rationale for extrapolating from genetic to sporadic disease (97).

Encouraging progress has been made with agents that target the VHL/HIF pathway in patients with advanced clear cell renal carcinoma, and clinical trials currently under way will provide insight into the clinical effectiveness of the combination of agents that target multiple parts of this pathway. Increased insights into the VHL, c-Met, BHD, and FH pathways should provide additional opportunities for the development of more effective forms of therapy for patients with each histologic type of kidney cancer.

Open Discussion

Dr. Atkins: How do you decide when to start treating patients with von Hippel-Lindau (VHL) with sunitinib?

Dr. Linehan: We have managed many people with many different kinds of tumors, and some of these people we have operated on two or three times. If you let the tumors keep growing, the patients will need surgery. If you let the tumors grow too big, they will spread.

Dr. Flaherty: We’ve considered using sorafenib in this patient population, but we have been cautious about using these drugs because of long-term tolerability. We’ve considered

Fig. 7. Germline FH mutations in HLRCC kindreds. From Toro et al. (98).

Fig. 8. Loss of FH impairs function of the tricarboxylic acid cycle and results in elevation of fumarate, which in turn stabilizes HIF. Elevated HIF drives transcription of key components of the glycolytic pathway, including GLUT and lactate dehydrogenase (LDH). Data in the table support the hypothesis that FH expression is inhibited by small interfering RNA (siRNA), as do HIF-1α and GLUT immunocytochemistry of HLRCC tumor specimens compared with normal kidney tissue. Data were taken from Isaacs et al. (93).
starting at half-dose sorafenib, 200 mg twice a day, which had activity in phase 1 trials. It might not be a full drug test, but in patients in whom long-term therapy might be needed, more intensive therapy is probably not doable.

Dr. Linehan: When would you stop therapy?

Dr. Flaherty: With sorafenib at a continuous standard dose of 400 mg twice a day, patients tolerate the drug better after several months of continued therapy. At 200 mg twice a day, we figured it would be even more tolerable and less challenging. We have had patients with renal cell carcinoma and melanoma who have been taking sorafenib for a couple of years, and their tolerance of single-agent therapy is good.

Dr. Sosman: Dr. Linehan, could you go back to an earlier phase of the disease to determine when the patients have a certain number of renal tumors or renal cysts and do a randomized study?

Dr. Linehan: Do you think sunitinib or sorafenib would be a better agent to study?

Dr. Sosman: In terms of tolerability, I might say bevacinumab, but that is risky.

Dr. George: We studied PTK/ZK in 11 patients with VHL. We looked for objective response in patients with hemangioendothelia in the cerebellum and spine, which we didn’t see. In addition, we used magnetic resonance imaging to determine different biologic effects. We are still analyzing that data. In terms of prevention, we have little experience with the long-term use of these drugs. It is difficult to determine therapy length and risks. We have seen complications, including spontaneous hemorrhage and hemangioblastoma.

Dr. McDermott: I have two patients with VHL who are currently receiving sorafenib. The first patient is a 56-year-old woman who has had metastatic kidney cancer for 7 years. She initially received interleukin 2 and achieved a PR. However, over the last 2 years, she has developed slow disease progression at several sites. She wondered if she should take sorafenib. Because of bleeding risk, I was hesitant to prescribe it because she did not have metastatic disease symptoms. Earlier this year, she developed leg weakness, secondary to renal cell carcinoma metastasis to her spine. After recovering from spinal surgery, she began taking sorafenib and has tolerated it without complication for 3 months. The second patient is a 44-year-old man with all of the known complications of VHL syndrome. He was referred to me to receive sorafenib for his metastatic kidney cancer to the brain and skin. His skin lesions have resolved, and his brain tumor has gotten smaller. However, because he was debilitated from his VHL, he could not tolerate continuous dosing of sorafenib. Furthermore, he has experience gross hematuria, likely from a retroperitoneal mass that has eroded into his ureter. While my experience is limited, because this class of drugs will not cure kidney cancer in patients with VHL, I would only recommend using them in patients with symptomatic kidney cancer because of the potential complications in both the malignant and benign tumors. Carefully monitored clinical trials for patients with VHL and renal cell carcinoma, while difficult to complete, should be initiated.

Dr. Atkins: Are there sporadic variants of hereditary leiomyomatosis renal cancer (HLRCC), and are there abnormalities in Birt Hogg Dubé (BHD) gene in patients with chromophobe tumors?

Dr. Linehan: For the HRLCC, if they exist, they are unusual. The BHD mutations have not been looked at extensively; however, in early attempts they have been found only infrequently.

Dr. Libermann: Do you see any deregulations of the fumarate hydratase enzyme in sporadic clear cell renal cancer?

Dr. Linehan: We have not looked at clear cell tumors for alterations of fumarate hydratase. The model that we proposed suggests that overaccumulation of fumarate essentially inactivates prolyl hydroxylases and then results in overaccumulation of HIF. This mechanism, however, may be only a small part of what we are dealing with in fumarate hydratase mutations.

References


Identification of the Genes for Kidney Cancer: Opportunity for Disease-Specific Targeted Therapeutics

W. Marston Linehan, Peter A. Pinto, Ramaprasad Srinivasan, et al.

*Clin Cancer Res* 2007;13:671s-679s.

Updated version
Access the most recent version of this article at:
http://clincancerres.aacrjournals.org/content/13/2/671s

Cited articles
This article cites 94 articles, 36 of which you can access for free at:
http://clincancerres.aacrjournals.org/content/13/2/671s.full#ref-list-1

Citing articles
This article has been cited by 6 HighWire-hosted articles. Access the articles at:
http://clincancerres.aacrjournals.org/content/13/2/671s.full#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, use this link
http://clincancerres.aacrjournals.org/content/13/2/671s.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.